Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer [1] [2] [3].
In Vivo, Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (100-500 μg, i.p., once every other day, for 2 weeks) significantly prolongs the survival time of transplants in C57BL/6 (H2d) mice with a heart transplantation model or pancreatic islet transplantation model[1]. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (500 μg, i.p., on day 14, 16, 18 and 20) reduces the number of T cells, B cells, and plasma cells in the lungs in female C57BL/6 mice injected with mRNA-LNP vaccines[2]. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (200 μg, i.p., twice a week, for 15 days) significantly reverses the inhibitory effect of Sin3B deficiency on tumor growth and reduces CD8+ T cell infiltration in male C57BL/6J wild-type mice bearing KPC1199 tumors[3].
In Vitro, Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (0.001-100 μg/mL, 1 h) effectively inhibits ligand binding (CXCL10 inhibited by 60%, CXCL11 inhibited by 41%) in BaF3 cells[1]. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (0-300 μg/mL, 1 h) significantly inhibits chemotaxis induced by CXCL10 (inhibition 61%) and CXCL11 (inhibition 67%) in ConA stimulated mouse spleen cells[1].
References:
[1]. Uppaluri R, et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation. 2008 Jul 15;86(1):137-47.
[2]. Kwon DI, et al. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice. Nat Immunol. 2025 Jun;26(6):908-919.
[3]. Zhang Z, et al. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer. Adv Sci (Weinh). 2024 Nov;11(43):e2402244.
In Vivo, Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (100-500 μg, i.p., once every other day, for 2 weeks) significantly prolongs the survival time of transplants in C57BL/6 (H2d) mice with a heart transplantation model or pancreatic islet transplantation model[1]. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (500 μg, i.p., on day 14, 16, 18 and 20) reduces the number of T cells, B cells, and plasma cells in the lungs in female C57BL/6 mice injected with mRNA-LNP vaccines[2]. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (200 μg, i.p., twice a week, for 15 days) significantly reverses the inhibitory effect of Sin3B deficiency on tumor growth and reduces CD8+ T cell infiltration in male C57BL/6J wild-type mice bearing KPC1199 tumors[3].
In Vitro, Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (0.001-100 μg/mL, 1 h) effectively inhibits ligand binding (CXCL10 inhibited by 60%, CXCL11 inhibited by 41%) in BaF3 cells[1]. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) (0-300 μg/mL, 1 h) significantly inhibits chemotaxis induced by CXCL10 (inhibition 61%) and CXCL11 (inhibition 67%) in ConA stimulated mouse spleen cells[1].
References:
[1]. Uppaluri R, et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation. 2008 Jul 15;86(1):137-47.
[2]. Kwon DI, et al. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice. Nat Immunol. 2025 Jun;26(6):908-919.
[3]. Zhang Z, et al. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer. Adv Sci (Weinh). 2024 Nov;11(43):e2402244.